29 Mar New Chief Medical Officer and member of Scientific Advisory Board appointed at Mironid
Mironid is delighted to announce the appointment of Dr Steve Felstead as Chief Medical Officer (CMO)
Dr Felstead retired from the position of Vice President, Head of Clinical Research, Pharmatherapeutics Division, Pfizer Inc in April 2014.
He joined Pfizer in 1989, having qualified in Medicine at Leeds University UK in 1982. Dr Felstead was appointed Head of Clinical Research in January 2009 responsible for the disciplines of Clinical Development and Pharmacology, Translational and Molecular Medicine, Preclinical and Clinical Statistics. Clinical Research was responsible for research projects up to Proof of Concept (Phase 2a) in the following Therapeutic Areas: Neuroscience, Cardiovascular and Metabolic Disease, Anti-Infectives, Pain and Regenerative Medicine. During this time Dr Felstead led the Pfizer team that laid the groundwork for the NIH/NCATS programme for systematic evaluation of drug repurposing.
From 2007 – 2008 Dr Felstead served as Development Therapeutic Area Head for Allergy and Respiratory medicines through to Phase 3b. Previously he held a number of project, line and administrative roles within drug development in the Sandwich, UK office over 15 years, and in Groton/New London, CT office for three years. These roles included Zithromax (azithromycin) clinical project manager in Europe, head of clinical development in Sandwich, Viagra (sildenafil) development team leader, Vfend (voriconazole) development team leader and Groton/New London development site head. Dr Felstead led the Viagra (sildenafil) team when the first pulmonary hypertension study was being designed, which led to the successful Revatio development program. From 2003-2007 he led the Celsentri/Selzentry (maraviroc) team through to successful transatlantic registration of this novel anti-retroviral medicine.
Since retirement Dr Felstead consults widely on various programmes for VC, Biotech, and Pharma. Dr Felstead is a member of Innovate UK, Biomedical Catalyst Late Stage Award committee, a member of AdALta Limited’s Scientific Advisory Board and a member of TRICAP (Tweed Renaissance Investment Capital) Group, which invests in emerging businesses.
Mironid is also delighted to announce the appointment of Prof Dorien Peters to our Scientific Advisory Board.
Prof. Dr. Dorien Peters is a molecular geneticist and cellular biologist at the Leiden University Medical Center in the Netherlands. Her research aims to obtain insight into the genetic, pathophysiologic and functional mechanisms of inherited disorders, most notably Polycystic Kidney Disease (PKD), to design new therapeutic approaches. As part of her investigative portfolio, she has generated several informative and unique mouse models for PKD that are being used to perform an in-depth analysis of the molecular alterations, to identify new drug targets and test potential therapies.
To translate fundamental and preclinical research to the clinic she has organised a number of multidisciplinary research networks to enhance fundamental, pharmacologic and clinical insights into PKD. She was project leader of multidisciplinary TranCyst Marie-Curie training-network (2012-2016) and is coordinating the Dutch ‘Developing Interventions to hold Progression of Autosomal Dominant Polycystic Kidney Disease (DIPAK)’ consortium. She is an active (co)-organiser of international conferences (FASEB meeting on PKD 2011, 2014; EMBO Cilia meetings 2016 and 2018). She is member of the scientific board of the Dutch Federation of Nephrology (NFN), was member of the Scientific board of the Dutch Kidney Foundation (2011-2017) and member of the board of Dutch Society of Human Genetics (2000-2008).
Prof. Dr. Peters has published more than 120 scientific publications. In 2013 she received the Lillian Jean Kaplan International Prize for Advancement in the Understanding of Polycystic Kidney Disease (PKD).